PUBLISHER: Grand View Research | PRODUCT CODE: 1888632
PUBLISHER: Grand View Research | PRODUCT CODE: 1888632
The global cardiac resynchronization therapy market size was estimated at USD 4.74 billion in 2024 and is projected to reach USD 8.21 billion by 2033, growing at a CAGR of 6.3% from 2025 to 2033. The market growth is driven by the rising prevalence of heart failure and associated conduction abnormalities, the increasing adoption of advanced implantable cardiac devices, and the expanding clinical evidence supporting the efficacy of CRT in improving survival and quality of life.
Technological advancements such as conduction system pacing (CSP), left bundle branch area pacing (LBBAP), and leadless or wireless CRT systems are enhancing therapeutic precision and reducing procedural complications, driving wider adoption among physicians. Favorable reimbursement policies in key markets, growing awareness of early heart failure management, and integration of AI-enabled remote monitoring for continuous patient follow-up are further accelerating market demand. In addition, ongoing clinical trials and new product launches by leading manufacturers, including next-generation MRI-compatible and Bluetooth-enabled CRT devices, continue to expand the therapeutic scope and patient eligibility for CRT therapy globally.
The increasing prevalence of cardiovascular diseases (CVDs) remains one of the primary factors driving the growth of the Cardiac Resynchronization Therapy (CRT) market. According to Oxford Academic (January 2025), the global age-standardized prevalence of CVD is estimated at approximately 7,179 cases per 100,000 populations, highlighting the persistent global burden of heart-related disorders. In the U.S., the prevalence of CVDs - including heart failure and cardiac arrhythmias continues to rise, largely due to sedentary lifestyles, obesity, and associated metabolic comorbidities. As reported by the American Heart Association (AHA) in January 2024, there were 931,578 CVD-related deaths, an increase of nearly 3,000 compared to the previous year. The age-adjusted death rate rose by 4.0%, reaching 233.3 deaths per 100,000 population, underscoring a concerning upward trajectory. This trend reflects a growing need for effective cardiac therapies that can improve functional outcomes and reduce mortality.
Global Cardiac Resynchronization Therapy Market Report Segmentation
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cardiac resynchronization therapy market report based on product, end-use and region: